Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study [abstract]
Journal of Pharmaceutical and Biomedical Analysis 204:114255
Quality control includes molecular weight verification, amino acid sequence accuracy and copper content analysis
Treatment plans are customized for each client, but most people do 5 injections per week over several weeks
She used ultrasound to locate my migrated lip filler, tested a small area first, and explained I was reactivenot allergic
Dasatinib+Quercetin (D+Q) inhibit multiple BCL-2 family pro-survival proteins and tyrosine kinasesbroad-mechanism senolytics with human clinical trial data (Mayo Clinic studies)